Global Rapid Drug Screen Market, By Component (Clear Plastic Collection Cup with Temperature Strip, Slotted Lid, Standard Lid, Test Card), Training (Web Based Training, CD-ROM Training, Onsite Training), Drug Type (Amphetamine, Methamphetamine, Marijuana Metabolite, Cocaine, Opiates, Phencyclidine, Barbiturates, Benzodiazepines, Methadone, Propoxyphene, Oxycodone/Oxymorphone, Hydrocodone/Hydromorphone, Others), End User (Workplace, Criminal Justice Systems and Law Enforcement Agencies, Drug Treatment Centers, Pain Management Centers, Schools and Colleges, Hospitals, Individual Users, Drug Testing Laboratories) – Industry Trends and Forecast to 2029.
Rapid Drug Screen Market Analysis and Size
According to the World Drug Report 2021, an estimated 275 million people worldwide aged 15-64, or one out of every 18 people in that age group, used drugs at least once in the previous year in 2019. In the same year, drug use killed nearly 500,000 people, while drug use disorders cost 18 million years of healthy life, primarily due to opioids. Similar increases in alcohol consumption have been observed, with consequences seen in the rising incidence of impaired driving.
Data Bridge Market Research analyses that the rapid drug screen market which was USD 8.3 million in 2021, would rocket up to USD 12.26 billion by 2029, and is expected to undergo a CAGR of 5% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Rapid Drug Screen Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Component (Clear Plastic Collection Cup with Temperature Strip, Slotted Lid, Standard Lid, Test Card), Training (Web Based Training, CD-ROM Training, Onsite Training), Drug Type (Amphetamine, Methamphetamine, Marijuana Metabolite, Cocaine, Opiates, Phencyclidine, Barbiturates, Benzodiazepines, Methadone, Propoxyphene, Oxycodone/Oxymorphone, Hydrocodone/Hydromorphone, Others), End User (Workplace, Criminal Justice Systems and Law Enforcement Agencies, Drug Treatment Centers, Pain Management Centers, Schools and Colleges, Hospitals, Individual Users, Drug Testing Laboratories)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
Abbott (U.S.), Thermo fisher Scientific Inc. (U.S.), Medtronic (Ireland), BD (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Drägerwerk AG & Co. KGaA (Germany), Laboratory Corporation of America Holdings (U.S.), Quest Diagnostics Incorporated (U.S.), Alfa Scientific Designs, Inc. (U.S.), Lifeloc Technologies Inc (U.S.), OraSure Technologies, Inc. (U.S.), Omega Laboratories, Inc. (U.S.)
Drug screening is a technique for detecting illegal substances in saliva, sperm, and other biological samples. During this process, potential drugs are identified and engineered to proceed to clinical trials until a candidate product is selected. This includes scanning large chemical collections for a specific biological operation in high-throughput screening assays.
Global Rapid Drug Screen Market Dynamics
- Government Initiatives
The US government is implementing a number of initiatives to monitor symptoms and determine whether a person is abusing drugs. For instance, the Patients and Communities Act of 2018 was a law passed by the country to combat drug abuse. Thus, rising drug and alcohol abuse, as well as strict regulations to detect intoxication in the body, are expected to propel the market growth during the forecast period.
- Drug screen use in hospitals
The accumulating evidence of increasing prevalence of drug misuse in the general population and on hospital wards, the need to detect drug misuse in order to reach an accurate diagnosis and the availability of effective interventions to help in-patients who are misusing substances and to treat presenting complications are the three reasons for screening for drug misuse in hospital settings. These are the certain reasons which propel the growth of market.
Furthermore, increasing drug screen usage for the prevalence of results, the ability to administer the entire test right on site, rising demand for cost effective tests and the prevalence of funds for the improvement of the healthcare sector will likely boost the growth of the rapid drug screen market during the forecast period of 2022-2029.
- Increasing applications from developing economies
Increasing applications from developing economies along with oral fluid testing and emergence of advanced technology which will further bring ample opportunities for the growth of the rapid drug screen market during the forecast period.
- Lack of healthcare infrastructure
Lack of improves healthcare infrastructure along with limited testing capabilities will obstruct the market's growth rate. However, inefficient storage procedures, high cost and the dearth of skilled personnel are some of the factors which are restraining the growth of this market.
This rapid drug screen market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rapid drug screen market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In August 2021, Quest Diagnostics and Select Health of South Carolina signed an agreement to expand Select Health's laboratory network for Medicaid and Medicare-Medicaid dual-eligible enrollees, as well as to improve access to diagnostics information services for members
- In May 2020, Psychemedics introduced a vaping panel test that detects the ingestion of marijuana, CBD, and nicotine drugs through any method, including electronic cigarettes or smoking
- In September 2020, Labcorp and Infirmary Health announced a multi-year collaboration agreement to provide laboratory services to patients and providers throughout the eastern Gulf Coast region
Global Rapid Drug Screen Market Scope
The rapid drug screen market is segmented on the basis of component, training, drug type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Clear Plastic Collection Cup with Temperature Strip
- Slotted Lid
- Standard Lid
- Test Card
- Web Based Training
- CD-ROM Training
- Onsite Training
- Marijuana Metabolite
- Criminal Justice Systems and Law Enforcement Agencies
- Drug Treatment Centers
- Pain Management Centers
- Schools and Colleges
- Individual Users
- Drug Testing Laboratories
Rapid Drug Screen Market Regional Analysis/Insights
The rapid drug screen market is analysed and market size insights and trends are provided by country, component, training, drug type and end user as referenced above.
The countries covered in the rapid drug screen market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the rapid drug screen market due to the occurrence of laws supporting drug screening along with availability of funding to curb drug abuse.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to the rising awareness drug screening.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Rapid Drug Screen Market Share Analysis
The rapid drug screen market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rapid drug screen market.
Some of the major players operating in the rapid drug screen market are:
- Abbott (U.S.)
- Thermo fisher Scientific Inc. (U.S.)
- Medtronic (Ireland)
- BD (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Drägerwerk AG & Co. KGaA (Germany)
- Laboratory Corporation of America Holdings (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Alfa Scientific Designs, Inc. (U.S.)
- Lifeloc Technologies Inc (U.S.)
- OraSure Technologies, Inc. (U.S.)
- Omega Laboratories, Inc. (U.S.)